Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013337 · ClinicalTrials.gov registry record · NA
Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT01013337 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 76 participants.
The verdict
NCT01013337, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase inhibitors. PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage I, stage II, or stage III breast cancer with aromatase inhibitor-related joint pain.
Interventions
- PROCEDURE acupuncture therapy
- PROCEDURE sham intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2009-05 |
| Est. Completion | 2016-04-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01013337
The ClinicalTrials.gov registry entry for NCT01013337 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which acupuncture therapy is the first listed.
NCT01013337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01013337 about?
NCT01013337 is a clinical study titled "Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain". RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase inhibitors. PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage I, stage II, or stage III breast cancer with aromatase inhibitor-related joint pain.
What is the current status of trial NCT01013337?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2009-05. Estimated completion is 2016-04-21.
What interventions are being tested in trial NCT01013337?
The interventions under investigation include: acupuncture therapy (PROCEDURE), sham intervention (PROCEDURE).
Who is sponsoring clinical trial NCT01013337?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.